Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2002

View Archived Issues

5G1.1 enters phase IIb trial in rheumatoid arthritis

Results from new collaboration between Alfacell and University of Frankfurt

In vivo Abeta amyloidogenic process inhibited by NC-531, a new GAG mimetic

Significant and sustained improvement seen on Exelon in subcortical vascular dementia

Effect of RPR-115135 on cytotoxicity of 5-FU in human tumor cells with different p53 status

Antiinflammatory effects demonstrated for adenosine uptake inhibitor in LPS-treated mice

Zelmac approved in Australia for symptomatic relief of IBS in women

Zoladex LA receives approval in Japan for prostate cancer

Italian researchers identify promising lead in search for third-generation NNRTIs

Enrollment completed in phase II at-home study of Femprox

Avanir outlicenses docosanol to Biopharm for Middle East and Gulf territories

Immune Network and Imaging Research Solutions to study dapsone in AD

Board recommends continuation of Biomira's phase IIb trial of BLP25 in NSCLC

Efficacy of levodopa in PD confirmed at international meeting

Phospholipid useful as antiinfluenza virus agent

Prostaglandin analogues claimed for use in congestive heart failure

Development of selective human PPARalpha activator reported by Kyorin

Sanofi-Synthelabo identifies new series of beta3-adrenoceptor agonists

AstraZeneca describes use of 4-aminoquinazoline derivatives in the treatment of solid tumors

New NOS inhibitors synthesized at Aventis

Toyama discloses novel benzophenone derivatives for use in arthritis in recent patent

Increased striatal dopaminergic function in schizophrenia linked to prefrontal cortical dysfunction

Two series of HMG-CoA reductase inhibitors with utility in lipid metabolism disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...